RxDoctor Payments Data

David Sola-Del Valle, MD

Ophthalmology · Boston, MANPI 1235423260

Payments from drug & device makers

$32,609in general payments, 2019–2025

Across 61 payments — averaging $534.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Thea Pharma Inc.$21K
  • AbbVie$4K
  • NEW World Medical,inc.$3K
  • Beaver-visitec International, Inc.$2K
  • Glaukos Corporation$726
  • Lensar, Inc.$633
  • plus $1K from 7 others

What the payments were for

  • Consulting fees$21,60066%
  • Speaking & faculty fees$5,85018%
  • Travel & lodging$2,8289%
  • Food & beverage$2,3107%
  • Education$210%

General payments by program year

20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,609 in reported general payments places this provider in the 85th percentile of 653 ophthalmology providers in Massachusetts.

See all ophthalmology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$274,651
Medicare patients
274
Services billed
1,790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate170$94,965
ZioptanTafluprost/Pf74$41,120
VyzultaLatanoprostene Bunod79$33,850
Alphagan PBrimonidine Tartrate70$26,836
Dorzolamide-TimololDorzolamide/Timolol/Pf146$26,668
LumiganBimatoprost50$23,625
Timoptic OcudoseTimolol Maleate/Pf26$21,691
Timolol MaleateTimolol Maleate/Pf48$19,861
IyuzehLatanoprost/Pf39$18,516
RocklatanNetarsudil Mesylat/Latanoprost34$17,756
Prednisolone Acetate511$16,643
Bromfenac Sodium22$9,391
Brimonidine Tartrate296$9,372
TafluprostTafluprost/Pf47$8,120
Brinzolamide37$7,925

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieAlphagan P, Lumigan, Combigan$4,363$56,615131 claims
Bausch & Lomb Americas Inc.Vyzulta$18$33,85079 claims
Thea Pharma Inc.Iyuzeh$21,064$18,51639 claims
AlconSimbrinza$428$5,41321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 653 ophthalmology providers in Massachusetts.

Other ophthalmology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →